Edwin Jabbari

We will aim to identify and validate baseline clinical, genetic, protein, imaging and digital biomarker features which are predictive of final diagnosis. Unless participants are withdrawn before completion of the study, the most recent diagnosis end-point if not pathological diagnosis will be diagnosis end-point 4 (48 months post-baseline) (see figure 2).

Parkinson’s disease (PD) is the commonest neurodegenerative cause of parkinsonism and, in terms of prevalence, is the fastest growing neurological disorder in the world. In the clinical setting, there are challenges in achieving an early and accurate diagnosis of PD due to clinical overlap with less common parkinsonian disorders, such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).

Parkinson’s disease (PD) is the commonest neurodegenerative cause of parkinsonism and, in terms of prevalence, is the fastest growing neurological disorder in the world. In the clinical setting, there are challenges in achieving an early and accurate diagnosis of PD due to clinical overlap with less common parkinsonian disorders, such as progressive supranuclear palsy (PSP), corticobobasal syndrome (CBS), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).